Previous close | 2.5500 |
Open | 2.3500 |
Bid | 1.7200 x 1100 |
Ask | 2.9600 x 1200 |
Day's range | 2.3300 - 2.4500 |
52-week range | 1.1500 - 5.9900 |
Volume | |
Avg. volume | 777,562 |
Market cap | 448.577M |
Beta (5Y monthly) | 2.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.7745 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.50 |
Montrouge, France, June 28, 2022 DBV Technologies to Participate in Upcoming EAACI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the hybrid in-person and virtual European Academy of Allergy and Clinical Immunology (EAACI) Annual Scientific meeting, July 1 – 3, 2022, in Prague, Czech Republic. Two scientific presentations have been accepted, including one non-cl
Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York. A we
Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregate $194 million private investment in public equity (PIPE) financing (corresponding to €181 million on the basis of an exchange rate of $1.0739 = €1.00 published by the European Central Bank on June 8, 2022) from the sale of 32,855,669